The University of Pennsylvania spinout said it has no intention to resume research and development work. To continue reading ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around $130, and later that year it climbed as high as $449, as investors ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

mRESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ...

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45 th Annual Health ...

CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted ...